Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459744 · ClinicalTrials.gov registry record · NA
An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 562
- Enrollment target
NCT01459744 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 562 participants.
The verdict
NCT01459744, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 562 participants
- Enrollment target
Study Summary
An Implantable Cardioverter-Defibrillator (ICD) is a device implanted in a patient's chest to monitor the heart rhythm and deliver shocks to terminate potentially lethal arrhythmias when necessary. While ICDs reduce sudden cardiac death, patients with ICDs eventually die of heart failure or other diseases. As patients near the end of life, physiologic changes (intrinsic and extrinsic to the heart) may affect the cardiac conduction system, leading to more arrhythmias and increasing the frequency of shocks. Because ICD shocks can cause pain and anxiety and may not prolong a life of acceptable quality, it is appropriate to consider deactivating the shocking function of ICDs as patients' clinical status worsens and death is near. This will be a randomized controlled trial of a physician centered counseling and education intervention to improve clinician-patient communication about the management of ICDs.
Interventions
- OTHER Control arm
- BEHAVIORAL Communication training for cardiologists.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 562 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01459744
The ClinicalTrials.gov registry entry for NCT01459744 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 562 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control arm is the first listed.
NCT01459744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01459744 about?
NCT01459744 is a clinical study titled "An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations". An Implantable Cardioverter-Defibrillator (ICD) is a device implanted in a patient's chest to monitor the heart rhythm and deliver shocks to terminate potentially lethal arrhythmias when necessary. While ICDs reduce sudden cardiac death, patients with ICDs eventually die of heart failure or other di...
What is the current status of trial NCT01459744?
This trial is currently completed. It is a NA study. The enrollment target is 562 participants. The study started on 2011-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01459744?
The interventions under investigation include: Control arm (OTHER), Communication training for cardiologists. (BEHAVIORAL).
Who is sponsoring clinical trial NCT01459744?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.